Role of molecular markers in identifying genetic disorders
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20242578Keywords:
Molecular markers, Genetic disorders, SNPs, Genetic screening, Personalized medicineAbstract
Molecular markers are critical tools in identifying genetic disorders, allowing for precise diagnosis, risk assessment, and personalized treatment approaches. They are classified into various categories, including single nucleotide polymorphisms (SNPs), short tandem repeats (STRs), and restriction fragment length polymorphisms (RFLPs), each serving distinct roles in genetic diagnostics. SNPs are widely used in genome-wide association studies (GWAS) to identify genetic predispositions to complex diseases, while STRs are valuable in diagnosing disorders like Huntington's disease. RFLPs, though less commonly used today, remain important in specific diagnostic contexts. The application of molecular markers spans a wide range of genetic disorders, from monogenic conditions such as cystic fibrosis (CF) to complex diseases like hereditary breast and ovarian cancer syndrome and fragile X syndrome. These markers enable early detection and targeted interventions, improving patient outcomes. However, several challenges hinder their widespread adoption, including difficulties in interpreting genetic data, limited access to genetic screening, and ethical concerns related to privacy and genetic discrimination. Future directions in the use of molecular markers for genetic screening involve integrating advanced technologies like next-generation sequencing and combining molecular data with other omics approaches to provide a more comprehensive understanding of genetic disorders. Addressing the challenges of data interpretation, accessibility, and ethical issues will be crucial in expanding the utility of molecular markers in clinical practice. The advancements in molecular marker technology and their applications in detecting specific genetic disorders hold promise for improving diagnostic accuracy and personalized treatment strategies. However, ensuring that these technologies are accessible and ethically implemented will be key to their success in transforming healthcare. The ongoing evolution of molecular markers and genetic screening technologies suggests a future where early diagnosis and personalized medicine become standard care for genetic disorders.
References
Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Human Genetics. 2012;90(1):7-24.
Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Human Genetics. 1995;56(1):265.
Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA. 2001;285(5):540-4.
Guttmacher AE, Collins FS. Genomic medicine-a primer. N Eng J Med. 2002;347(19):1512-20.
McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JPA, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nature Rev Genet. 2008;9(5):356-69.
Burke W, Khoury MJ, Stewart A, Zimmern RL. The path from genome-based research to population health: development of an international public health genomics network. Genet Med. 2006;8(7):451-8.
Consortium IH. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164):851.
Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992;12(2):241-53.
Botstein D, White RL, Skolnick M, Davis RW. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Human Genet. 1980;32(3):314.
Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nature Rev Genet. 2015;16(1):45-56.
King M-C, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-46.
Hagerman RJ, Berry-Kravis E, Hazlett HC, Donald BB, Herve M, Frank RK, et al. Fragile X syndrome. Nature Rev Dis Primers. 2017;3(1):1-19.
Manolio TA, Collins FS, Cox NJ, David BG, Lucia AH, David JH, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747-53.
Feero WG, Guttmacher AE, Collins FS. Genomic medicine-an updated primer. N Eng J Med. 2010;362(21):2001-11.
McGuire AL, Burke W. Health system implications of direct-to-consumer personal genome testing. Public Health Genom. 2010;14(1):53-8.
